No Data
No Data
Erasca Kicks off Phase III Trial for Naporafenib Combo Therapy in Melanoma
Express News | Erasca Inc - Favorable Mos and Mpfs Demonstrated in Pooled Analysis of Phase 1B and Phase 2 Trials in Nrasm Melanoma
Express News | Erasca Inc - Randomized Stage 1 Readout for Naporafenib Plus Trametinib Vs. Trametinib Monotherapy Expected in 2025
Express News | Erasca Initiates Seacraft-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients With Nras-Mutant Melanoma
Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients With NRAS-Mutant Melanoma
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the initiation of the global SEACRAFT-2 Phase 3 trial evaluating the pan-RAF inhibitor naporafenib in combination with the MEK inhibitor trametinib (MEKINIST) in patients with NRAS-mutant (NRASm) melanoma.
Erasca to Present at Upcoming Investor Conferences in June
PDF Version SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializi
No Data